RxDoctor Payments Data

Michael Maccini, MD

Urology · Spokane, WANPI 1861767121

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,487 of the $9,788 with a category attached, or 76.5%. 45 manufacturers reported payments, led by Teleflex LLC at 29.0% of the total. Reporting peaked in 2024 at $3,038 and has fallen 63.5% since, to $1,108 in 2025.

$9,788in general payments, 2019–2025

Across 188 payments — averaging $52.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$3K
  • Neotract Inc.$1K
  • EDAP Technomed Inc$687
  • AbbVie$615
  • Johnson & Johnson$582
  • Ferring Pharmaceuticals Inc.$376
  • plus $4K from 39 others

What the payments were for

  • Travel & lodging$2,23723%
  • Food & beverage$7,48776%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,788 in reported general payments places this provider in the 85th percentile of 274 urology providers in Washington.

See all urology providers in Washington

Medicare billing

Part B allowed, 2024
$662,100
Medicare patients
558
Services billed
4,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide15$203,523
MyrbetriqMirabegron27$20,434
GemtesaVibegron15$7,543
Tamsulosin Hcl370$5,703
Potassium Citrate ErPotassium Citrate12$3,166
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst65$1,736
Oxybutynin Chloride ErOxybutynin Chloride87$1,382
Finasteride80$1,253
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen152$658
Oxybutynin Chloride71$605
Ciprofloxacin Hcl57$385
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim38$228
Alfuzosin Hcl ErAlfuzosin Hcl11$191
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$136
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen29$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$372$223,95742 claims
Sumitomo Pharma America, Inc.Gemtesa$372$7,54315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 274 urology providers in Washington.

Other urology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →